Related Experiment Videos
Moclobemide overdose
P G Myrenfors1, T Eriksson, C S Sandsted
1Swedish Poison Information Centre, Karolinska Hospital, Stockholm.
Abstract:
Moclobemide is a recently introduced short-acting, selective and reversible monoamine oxidase inhibitor, type A, with few and mild side-effects at therapeutic doses. Fifteen reported cases of moclobemide overdose were studied in detail and are presented here. While pure mechanism overdosage seems benign, a combination with tricyclic antidepressants may result in serious poisoning even when the moclobemide overdose is modest.
Insights
Moclobemide overdose alone appears safe, but combining it with tricyclic antidepressants can lead to severe poisoning. This highlights the importance of careful medication management for patients taking monoamine oxidase inhibitors.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Neuroscience
Background:
- Moclobemide is a novel, short-acting, selective, and reversible monoamine oxidase A inhibitor.
- It exhibits few and mild side effects at therapeutic doses.
- Understanding overdose effects is crucial for patient safety.
Purpose of the Study:
- To analyze reported cases of moclobemide overdose.
- To determine the safety profile of moclobemide in overdose scenarios.
- To investigate potential interactions leading to severe poisoning.
Main Methods:
- Detailed review of fifteen reported cases of moclobemide overdose.
- Analysis of patient outcomes based on substances ingested.
Main Results:
- Pure moclobemide overdose cases presented as benign.
- Cases involving co-ingestion with tricyclic antidepressants showed serious poisoning.
- Severe toxicity occurred even with modest moclobemide overdose when combined with TCAs.
Conclusions:
- Isolated moclobemide overdose is generally benign.
- Concurrent use of moclobemide and tricyclic antidepressants poses a significant risk of severe poisoning.
- Clinicians must exercise caution when prescribing moclobemide to patients on tricyclic antidepressants.